| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 274.27 mm | 274.27 mm | 274.27 mm | 274.27 mm | 274.27 mm | |
| Cash burn (monthly) | 8.62 mm | 360.50 k | 11.85 mm | 11.52 mm | 3.31 mm | |
| Cash used (since last report) | 45.69 mm | 1.91 mm | 62.87 mm | 61.08 mm | 17.56 mm | |
| Cash remaining | 228.58 mm | 272.36 mm | 211.40 mm | 213.19 mm | 256.71 mm | |
| Runway (months of cash) | 26.5 | 755.5 | 17.8 | 18.5 | 77.5 | |
| 13F holders | Current |
|---|---|
| Total holders | 83 |
| Opened positions | 19 |
| Closed positions | 14 |
| Increased positions | 33 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 172.44 bn |
| Total shares | 72.86 mm |
| Total puts | 31.50 k |
| Total calls | 82.70 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Redmile | 15.67 mm | $49.36 bn |
| Prosight Management | 9.64 mm | $30.35 bn |
| HPWH TH | 7.45 mm | $275.20 mm |
| Orbimed Advisors | 4.53 mm | $14.28 bn |
| BlackRock | 4.40 mm | $13.86 bn |
| Oaktree Capital Group Holdings GP | 4.28 mm | $19.01 mm |
| AZN AstraZeneca | 4.01 mm | $0.00 |
| MS Morgan Stanley | 3.04 mm | $9.58 bn |
| BAC Bank of America | 2.50 mm | $7.87 bn |
| Auven Therapeutics | 2.23 mm | $11.09 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Feb 25 | Ameet Mallik | Common Shares | Grant | Acquire A | No | No | 1.61 | 650,000 | 1.05 mm | 1,579,005 |
| 13 Feb 25 | Lisa Michelle Kallebo | Common Shares | Grant | Acquire A | No | No | 1.61 | 41,900 | 67.46 k | 77,897 |
| 13 Feb 25 | Jose Carmona | Common Shares | Grant | Acquire A | No | No | 1.61 | 240,000 | 386.40 k | 541,892 |
| 13 Feb 25 | Graham Peter J | Common Shares | Grant | Acquire A | No | No | 1.61 | 220,000 | 354.20 k | 408,542 |
| 13 Feb 25 | Mohamed Zaki | Common Shares | Grant | Acquire A | No | No | 1.61 | 230,000 | 370.30 k | 462,888 |
